Skip to main content
Tessa NewsLink
Paste a health news link, or browse
Latest checks

Source study unconfirmed

Story checked

1nhaler secures £2.2 million to continue late-stage development (opens in a new tab)

news-medical.net · 2026-11-03

Short answerEvidenceSource

Short answer

Source study unconfirmed

Study not confirmed.

The search did not establish a source study for this article. Its claims remain unverified; this does not mean they are incorrect.

15 candidate papersExplore the search results

These papers were considered as possible sources, but none could be confirmed as the study behind this story.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

No single source study could be confirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

View article claims
3

Search result

Source study unconfirmed.

The search identified related research but did not establish a single source study. Related papers are provided for context, not as verification of the article's claims.

The literature search

15 candidate papers

Studies identified during the search

These papers appeared in the search for the story’s source. None was confirmed as a direct match. Inclusion here does not mean a paper supports or contradicts the story, or that its full text was reviewed.

Show 11 more search results
Then inspect each claim

Evidence layer

Claim by claim

The article's claims are listed below. Without a confirmed source study, they have not been assessed as supported or unsupported.

Claim 1 of 4Not checked1nhaler has secured £2.2 million in follow-on funding to progress its novel pop-up cardboard inhaler towards first regulatory approval.View evidenceHide evidence

As stated£2.2 million

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 2 of 4Not checkedThe funding will help complete technical transfer of 1nhaler Salbutamol into contract manufacturing, produce clinical trial material, and support a small clinical trial for a regulatory filing targeted for late 2027.View evidenceHide evidence

As statedlate 2027

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 3 of 4Not checkedThe 1nhaler platform is described as a cardboard, credit-card-sized single-dose dry powder inhaler designed to be simpler and cheaper to manufacture at scale, with potential uses beyond respiratory disease.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Claim 4 of 4Not checkedThe lead product combines the new device with salbutamol, an established asthma medicine.View evidenceHide evidence

Not checked

No source study was confirmed for this article. This claim remains unverified, rather than assessed as supported or unsupported.

Finally, the search trail

Method layer

Study not confirmed.

The search results are available for you to inspect. Without a confirmed source study, they cannot establish whether the story’s claims are supported or contradicted.

Search results

Candidate papers, not confirmed sources.

PubMed, Europe PMC, Crossref · 15 candidate papers

Candidate

Broncho dilator response to salbutamol delivered by metered dose inhaler with spacer versus dry powder inhaler in acute asthma in children

7.2 Paediatric Asthma and Allergy · 2016 · Crossref

Source (opens in a new tab)
Candidate

A COMPARATIVE STUDY OF METERED DOSE INHALER WITH SPACER AND DRY POWDER INHALER FOR DELIVERY OF SALBUTAMOL IN ACUTE EXACERBATIONS OF BRONCHIAL ASTHMA

PARIPEX INDIAN JOURNAL OF RESEARCH · 2021 · Crossref

Source (opens in a new tab)

Explore all search results